EHA 2024 | Phase II trial of obinutuzumab, alone and combined with vemurafenib, in R/R hairy cell leukemia
Enrico Tiacci, MD, University of Perugia, Perugia, Italy, discusses the findings of a multicenter Phase II trial evaluating obinutuzumab as a monotherapy and in combination with vemurafenib (a BRAF inhibitor) in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL). Around half of the patients in the study responded well to obinutuzumab monotherapy, and those who did not exhibit a response were successfully salvaged with the combination therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite/Gilead, Deciphera, Innate Pharma, Roche.
